TrazenTin Duo Tablet 2.5/500 mg
Linagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
DaeHwa Pharmaceutical Co., Ltd.
MFDS item code 201907007 · Approved 2019.10.01
This product's status changed to Expired on 2024.10.01. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes, aiding in effective blood sugar regulation by the combined action of linagliptin and metformin.
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of the individual components: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin, the dose should be increased gradually. 1. Patients not currently treated with metformin: For patients with no previous experience with antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy, the initial dose is one tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to one tablet of this medicine 2.5/1000 mg twice daily. 2. Switching from concomitant treatment with linagliptin and metformin: Patients switching from concomitant treatment with linagliptin and metformin to this medicine should take the same doses of linagliptin and metformin they were previously taking as the initial dose. 3. Patients unable to achieve adequate glycemic control with concomitant insulin and metformin: The initial dose should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be needed to reduce the risk of hypoglycemia (see section 2, Patients Requiring Cautious Administration, under Precautions for Use). No studies have been conducted to evaluate the safety and efficacy of switching patients from other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. As the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, discontinue this medicine immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see section 1, Patients Who Must Not Take This Medicine, under Precautions for Use).
This medication may cause a serious side effect known as lactic acidosis, therefore it should not be administered to patients with impaired renal function or those with cardiac or liver issues. Additionally, it is prohibited for use by people who have allergies to any components of this medication, individuals with type 1 diabetes, or women who are pregnant or breastfeeding. Be cautious when taking this medication with sulfonylureas or insulin due to the risk of hypoglycemia, and frequent monitoring of blood sugar levels is necessary. Elderly patients with reduced renal function or those taking medications that may affect renal function should have their kidney function tested regularly, and dose adjustments should be made as needed. If you experience acute infections, dehydration, severe trauma, or are undergoing surgery or receiving iodinated contrast media, take a break from this medication temporarily and resume after renal function is stabilized. While using this medication, gastrointestinal disturbances (abdominal pain, diarrhea, nausea, vomiting, etc.) may occur, and if symptoms are severe, consult your physician. Moreover, this medication can cause vitamin B12 deficiency, so patients taking it long-term should have their blood vitamin B12 levels checked regularly. If skin abnormalities such as acute pancreatitis or bullous pemphigoid occur, discontinue the medication immediately and inform healthcare professionals. Women who are pregnant or planning to become pregnant should not take this medication, and it is also advisable to avoid use while breastfeeding. The safety of this medication for children and adolescents has not been established, and it is not recommended for children under 10 years or teenagers aged 10 to 17. There is no research on the effects on driving or operating machinery, but caution is needed due to the possibility of hypoglycemia or dizziness. In case of overdose, serious conditions such as lactic acidosis may occur, requiring an immediate visit to the hospital for treatment, and blood dialysis may be necessary. This medication should be stored in a sealed container away from moisture and direct sunlight, and should be kept out of the reach of children. Avoid transferring it to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so it should be stored in a tightly closed container. It is advisable to maintain room temperature between 1 to 30 degrees Celsius for storage. Storing it this way will help retain the medication's effectiveness for a long time.
Bright yellow, oval-shaped film-coated tablet with two convex sides
30 tablets/box [6 tablets/PTP x 5]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Linagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
DaeHwa Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.